PIRAMAL PHARMA LIMITED

BSE: PPLPHARMA543635ISIN INE0DK501011

Healthcare
Pharmaceuticals
BSE 500

BSE listing

Share price

₹208.00+3.50 (+1.71%)

as of 18 Sep 2026

52W high: ₹231.85
52W low: ₹132.50
Off 52W high: -10.29%
1M return: -0.74%
3M return: +30.98%
6M return: +50.45%
1Y return: +2.31%
20D avg volume: 3,86,565
50 DMA: ₹202.07
200 DMA: ₹173.18

Key ratios Consolidated

Market cap: ₹27,692 Cr
Current price: ₹208.00
52W high / low: ₹231.85 / ₹132.50
Face value: ₹10.00
P/E: -88.30
P/B: —
EPS (TTM): ₹-2.36
Book value / share: —
ROE: —
ROCE: 0.80%
Operating margin: —
Net margin: —
Debt / equity: 0.67
Net debt: ₹4,296 Cr
Interest cover: 0.32
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 112.9 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	2,270	2,752	2,140	2,044	1,934	2,754	2,204	2,242	1,951	2,552	1,959	1,911
	89.41	46.06	43.24	65.60	58.40	42.03	12.13	61.11	19.54	26.38	61.51	49.19
	2,386	2,593	2,246	2,170	2,110	2,540	2,167	2,200	2,038	2,333	1,982	1,940
	724.77	482.59	505.48	483.42	524.35	203.68	805.44	575.14	471.48	400.08	627.63	531.72
	420.24	336.03	376.84	374.83	342.83	546.72	161.06	394.77	314.77	436.06	227.93	243.59
	675.63	586.02	599.85	611.46	618.59	612.01	556.24	559.53	579.69	494.15	523.78	516.03
	88.08	82.99	89.24	82.42	86.15	103.68	103.31	107.64	106.96	114.22	105.88	109.87
	223.55	218.38	212.74	202.84	197.28	242.76	196.81	192.22	184.55	196.13	186.32	184.51
	546.82	649.57	557.98	571.07	514.37	626.09	—	544.14	—	—	—	—
	-27.02	205.20	-63.01	-60.97	-118.33	256.58	49.75	102.86	-67.48	245.96	37.68	20.45
	0.00	-175.77	-41.11	0.00	20.74	0.00	0.00	0.00	0.00	-30.52	-32.27	0.00
	-27.02	29.43	-104.12	-60.97	-97.59	256.58	49.75	102.86	-67.48	215.44	5.41	20.45
	61.93	51.83	42.33	53.04	2.68	119.30	63.12	97.53	43.56	126.21	9.25	34.54
	-69.39	-8.82	-136.19	-99.22	-81.70	153.50	3.68	22.59	-88.64	101.27	10.11	5.02
	-0.52	-0.07	-1.03	-0.75	-0.62	1.16	0.03	0.17	-0.67	0.77	0.08	0.04
Key metrics
	284.61	330.80	197.86	224.29	185.84	603.02	349.87	402.72	224.03	525.79	297.61	314.83
	12.50%	12.00%	9.20%	11.00%	9.60%	21.90%	15.90%	18.00%	11.50%	20.60%	15.20%	16.50%
	-3.10%	-0.30%	-6.40%	-4.90%	-4.20%	5.60%	0.20%	1.00%	-4.50%	4.00%	0.50%	0.30%
	—	0.90%	—	0.20%	—	3.00%	—	—	—	—	—	—
	17.40%	-0.10%	-2.90%	-8.80%	-0.90%	7.90%	12.50%	17.30%	—	—	—	—
	15.10%	-105.70%	-3,800.80%	-539.20%	7.80%	51.60%	-63.60%	350.00%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23
Income statement
	9,205	8,869	9,151	8,171	7,082
	244.31	213.30	134.81	175.39	225.11
	9,395	9,120	8,944	8,164	7,474
	2,196	1,996	2,056	1,977	1,682
	1,508	1,431	1,417	1,176	952.20
	2,473	2,416	2,307	2,030	1,896
	342.73	340.80	421.59	448.49	344.18
	857.51	831.24	816.34	740.57	676.69
	2,325	2,293	2,167	—	—
	54.20	-37.12	341.71	182.59	-167.52
	-216.88	-196.14	0.00	-62.79	-6.96
	-162.68	-233.26	341.71	119.80	-174.48
	209.13	149.88	323.51	161.47	66.31
	-313.62	-325.94	91.13	17.82	-186.46
	-2.37	-2.46	0.69	0.14	-1.57
Key metrics
	1,038	938.78	1,580	1,309	846.39
	11.27%	10.60%	17.30%	16.00%	12.00%
	-3.41%	-3.70%	1.00%	0.20%	-2.60%
	—	0.80%	6.40%	—	—
	—	-3.10%	12.00%	15.40%	—
	—	-457.70%	411.40%	109.60%	—
	—	762.57	227.92	—	—
	—	-5.07	9.79	—	—
	—	0.67	0.58	—	—
	—	4,296	4,351	—	—
	—	112.9	124.7	—	—
Balance sheet
	—	17,965	15,678	—	—
	—	7,192	5,797	—	—
	—	1,200	368.98	—	—
	—	2,158	2,350	—	—
	—	3,064	2,313	—	—
	—	548.67	551.80	—	—
	—	4,451	4,176	—	—
	—	2,479	1,534	—	—
	—	4,758	3,766	—	—
	—	5,495	4,720	—	—
	—	1,196	1,506	—	—
	—	4,300	3,214	—	—
	—	8,163	8,125	—	—
Cash flow
	—	1,653	892.30	—	—
	—	-826.03	-477.46	—	—
	—	-38.97	-440.83	—	—
	—	890.02	664.38	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	1,125	1,489	1,196	1,127	969.88	1,690	1,248	1,284	1,063	1,525	1,024	994.24
	114.63	183.69	96.15	201.97	180.92	39.51	24.70	106.38	36.76	53.19	33.11	89.08
	1,090	1,275	1,110	1,082	1,008	1,365	1,114	1,115	988.30	1,216	967.59	987.13
	649.70	234.93	347.06	350.95	409.76	336.72	474.23	380.22	405.76	417.52	444.94	356.76
	234.64	194.03	264.03	215.85	192.27	149.93	174.42	232.81	176.44	145.86	171.21	156.09
	216.34	166.55	187.80	188.52	201.95	198.96	173.55	176.72	186.96	152.88	150.56	151.44
	16.36	19.50	16.84	20.38	23.23	30.56	29.17	29.95	24.88	27.66	17.42	28.22
	65.73	70.12	64.69	61.25	59.44	61.17	55.46	53.61	51.85	52.50	51.56	50.83
	297.62	364.95	307.86	355.04	297.44	351.29	—	—	—	—	—	—
	149.48	397.42	181.87	247.41	142.58	364.36	159.41	275.71	111.66	362.67	89.66	96.19
	0.00	-65.57	-26.94	0.00	0.00	0.00	—	—	—	—	—	—
	149.48	331.85	154.93	247.41	142.58	364.36	159.41	275.71	111.66	362.67	89.66	96.19
	36.00	70.22	26.02	51.08	29.44	87.09	40.61	65.65	26.39	89.59	15.32	19.03
	113.48	261.63	128.91	196.33	113.14	277.27	118.80	210.06	85.27	273.08	74.34	77.16
	0.85	1.97	0.97	1.48	0.85	2.09	0.90	1.59	0.64	2.06	0.56	0.61
Key metrics
	231.57	421.47	236.46	329.04	225.25	456.09	244.04	359.27	188.39	442.83	158.64	175.24
	20.60%	28.30%	19.80%	29.20%	23.20%	27.00%	19.50%	28.00%	17.70%	29.00%	15.50%	17.60%
	10.10%	17.60%	10.80%	17.40%	11.70%	16.40%	9.50%	16.40%	8.00%	17.90%	7.30%	7.80%
	—	3.90%	—	3.10%	—	4.90%	—	—	—	—	—	—
	16.00%	-11.90%	-4.20%	-12.20%	-8.80%	10.80%	21.90%	29.20%	—	—	—	—
	0.30%	-5.60%	8.50%	-6.50%	32.70%	1.50%	59.80%	172.20%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23
Income statement
	4,937	4,782	5,286	4,390	3,443
	596.44	662.73	207.35	202.06	341.07
	4,557	4,475	4,582	4,085	3,654
	1,583	1,343	1,597	1,546	1,166
	908.55	866.18	733.60	624.91	548.69
	759.21	744.82	736.19	613.93	548.50
	73.08	79.95	114.56	107.10	115.87
	261.79	255.50	222.09	205.26	192.08
	1,325	1,325	1,263	—	1,029
	976.18	969.28	911.14	507.62	130.65
	-92.51	-92.51	0.00	—	-6.96
	883.67	876.77	911.14	507.62	123.69
	183.32	176.76	219.74	116.40	54.19
	700.35	700.01	691.40	391.22	69.50
	5.27	5.28	5.22	3.05	0.58
Key metrics
	1,219	1,212	1,248	819.98	431.64
	24.68%	25.30%	23.60%	18.70%	12.50%
	14.19%	14.60%	13.10%	8.90%	2.00%
	—	10.60%	12.70%	—	—
	—	-9.50%	20.40%	27.50%	—
	—	1.20%	76.70%	462.90%	—
	—	1,031	265.99	—	—
	—	1.90	0.79	—	—
	—	0.09	0.16	—	—
	—	150.86	1,058	—	—
	—	96.8	116.5	—	—
Balance sheet
	—	11,753	10,392	—	—
	—	4,398	3,536	—	—
	—	559.03	163.87	—	—
	—	1,406	1,667	—	—
	—	1,873	1,205	—	—
	—	372.20	391.85	—	—
	—	2,022	2,011	—	—
	—	2,011	1,185	—	—
	—	2,766	2,306	—	—
	—	709.89	1,222	—	—
	—	289.03	865.09	—	—
	—	420.86	356.84	—	—
	—	8,141	7,453	—	—
Cash flow
	—	1,328	548.77	—	—
	—	-317.83	-549.98	—	—
	—	-615.13	-61.74	—	—
	—	297.55	282.78	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +11.57%
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: +115.96%
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): -4.92%
Profit YoY (TTM): -2.63%

Consolidated

Sales CAGR 3Y: +7.79%
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): +0.78%
Profit YoY (TTM): -419.79%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 34.79%

Holder	Type	Holding	Previous	Change
The Sri Krishna Trust (through its Trustee Mr. Ajay G Piramal and Dr. (Mrs.) Swati A. Piramal)	Promoter Group	26.51%	—	—
CA Alchemy Investments	Public	17.93%	—	—
Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund	Public	7.68%	—	—
V3 Designs LLP	Promoter Group	3.23%	—	—
PRL Realtors LLP	Promoter Group	2.99%	—	—
East Bridge Capital Master Fund I Ltd	Public	2.00%	—	—
Indiahold Limited	Public	1.30%	—	—
Piramal Welfare Trust	Promoter Group	0.79%	—	—
Semplice Corporate Solutions Private Limited (Formerly known as AASAN Corporate Solutions Private Limited)	Promoter Group	0.67%	—	—
The Ajay G. Piramal Foundation	Promoter Group	0.33%	—	—
Mr. Anand Piramal	Promoter Group	0.07%	—	—
Anand Piramal Trust	Promoter Group	0.05%	—	—
Mr. Ajay G. Piramal	Promoter	0.04%	—	—
Nandini Piramal Trust	Promoter Group	0.04%	—	—
Mr. Peter DeYoung	Promoter Group	0.03%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Please refer attached file18 Sep 2026 · Company Update / General
Please refer attached file14 Sep 2026 · Company Update / General
Please refer attached file8 Sep 2026 · Company Update / Analyst / Investor Meet
Please refer attached file3 Sep 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG26 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Please refer attached file24 Aug 2026 · Company Update / General
Please find enclosed intimation of acquisition of additional stake in Yapan Bio Private Limited18 Aug 2026 · Company Update / Acquisition
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG18 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Please find enclosed intimation of exercise of call option for acquisition of additional equity stake in Yapan Bio Private Limited10 Aug 2026 · Company Update / General
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201510 Aug 2026 · Company Update / Analyst / Investor Meet
Please refer attachment3 Aug 2026 · Company Update / General
Please find enclosed details of Earning call Transcript held on 30th July 2026.31 Jul 2026 · Company Update / Earnings Call Transcript
Report of the Scrutinizer along with the voting results of the businesses transacted at the AGM30 Jul 2026 · AGM/EGM / AGM
Proceedings and Voting Results of the 6th Annual General Meeting of the Company30 Jul 2026 · AGM/EGM / AGM
Please find enclosed intimation of audio recordings of the conference call held today 30th July, 2026.30 Jul 2026 · Company Update / Analyst / Investor Meet
Please see enclosed Investor Presentation for Q1 FY 2729 Jul 2026 · Company Update / Investor Presentation
Please see enlcosed Press Release for Q1 FY 2729 Jul 2026 · Company Update / Press Release / Media Release
Please find enlcosed UFR Q1 FY 27.29 Jul 2026 · Result / Financial Results
Please find enclosed outcome of Board Meeting of Piramal Pharma Limited held on 29th July, 202629 Jul 2026 · Board Meeting / Outcome of Board Meeting
Grant of Stock Options pursuant to Piramal Pharma Limited - Employee Stock Option and Incentive Plan 202229 Jul 2026 · Company Update / General
Please refer attachment.24 Jul 2026 · Company Update / General
Please find enclosed intimation of Analyst Meet scheduled to be held on 30th July 2026.20 Jul 2026 · Company Update / Analyst / Investor Meet
Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....20 Jul 2026 · Board Meeting / Board Meeting
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund17 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Successful closure of US FDA Inspection at Piramal Pharma''s manufacturing facility located at Sellersville (USA) facility9 Jul 2026 · Company Update / General
Newspaper Advertisement for dispatch of notice of the 6th Annual General Meeting and E-Voting information4 Jul 2026 · Company Update / Newspaper Publication
Business Responsibility and Sustainability Reporting for the Financial Year 2025-263 Jul 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Notice of the 6th Annual General Meeting and Annual Report for the financial year 2025-263 Jul 2026 · Others / Reg. 34 (1) Annual Report
Notice of the 6th Annual General Meeting and Annual Report for the financial year 2025-263 Jul 2026 · AGM/EGM / AGM
Please refer attached file29 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Please refer attached file23 Jun 2026 · Company Update / General
The Exchange has sought clarification from Piramal Pharma Ltd on June 23, 2026, with reference to news appeared in https://www.ndtvprofit.com dated June 23, 2026, quoting "Piramal Pharma ....23 Jun 2026 · Company Update / Clarification
Newspaper Advertisement for information regarding 6th Annual General Meeting of the Company19 Jun 2026 · Company Update / Newspaper Publication
Please find enclosed intimation of allotment of ESOPs.5 Jun 2026 · Company Update / Allotment of ESOP / ESPS
Permanent revocation of closure directions for Company''s Dahej Site3 Jun 2026 · Company Update / General
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 20151 Jun 2026 · Company Update / Analyst / Investor Meet
Please find enclosed herewith the Annual Secretarial Compliance Report for the Financial Year 2025-2026.22 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201519 May 2026 · Company Update / Analyst / Investor Meet
Please refer attached file18 May 2026 · Company Update / General
Please refer attached file10 May 2026 · Company Update / General

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 0.1400	16 Jul 2025	16 Jul 2025	—
Final Dividend - Rs. - 0.1100	12 Jul 2024	12 Jul 2024	—

Board meetings

29 Jul 2026 Board Meeting - Financial Results